Hereditary Angioedema (HAE) Therapeutics Market Size

Hereditary Angioedema Therapeutics Market Size

Hereditary Angioedema Therapeutics Market size was valued at USD 4.1 billion in 2023 growing at a CAGR of 9.2% between 2024 and 2032. The key factors driving the growth of the market include rising awareness of hereditary angioedema (HAE) and advancements in diagnostic technology, such as improved genetic testing, leading to more diagnoses and increasing the number of patients requiring effective treatment options.

For instance, according to the Rare Disease Advisor Report, HAE episodes result in 15,000–30,000 emergency department visits in the U.S. each year. A survey of U.S. physicians revealed that the average time to diagnose HAE can range from 0–6 months to over 10 years, with fewer than 38% of patients receiving an accurate diagnosis within 1–3 years after symptoms appear. Enhanced awareness of HAE among healthcare professionals and patients, coupled with advancements in targeted therapies, such as the development of new complement inhibitors and bradykinin B2 receptor antagonists, is anticipated to foster market growth.
 

Hereditary angioedema (HAE) is an autosomal dominant disease caused by either a lack of C1-inhibitor protein or dysfunctional C1-inhibitor protein. The most feared complication of HAE is upper airway swelling, which can lead to asphyxiation. HAE therapeutics refer to medical treatments and interventions specifically designed to manage and alleviate the symptoms of the disease.